Galimedix begins study of GAL-101 eye drops for dry AMD

Galimedix Therapeutics announced the initiation of its phase 2 eDREAM study to assess the safety and efficacy of GAL-101 eye drops in patients with dry age-related macular degeneration, according to a company press release.

“GAL-101 eye drops have already shown an excellent safety and tolerability profile in phase 1 clinical testing, and compelling efficacy with GAL-101 protecting neuronal retinal cells from toxic damage has been demonstrated in relevant ophthalmic preclinical models,” Hermann Russ, MD, PhD, co-founder and CSO of Galimedix, said in the release. “Despite recent advances, there remains a need to offer patient-friendly, safe and effective treatment options for this disease, and we look forward to seeing the results from this important trial.”

GAL-101 targets misfolded A monomers to prevent the formation of toxic A oligomers and protofibrils. The drug is currently being developed for both oral and topical formulations to treat AMD, glaucoma and Alzheimer’s disease.

Up to 110 participants will be enrolled in the study, with the primary endpoint being reduction in rate of change of geographic atrophy lesions. Researchers will also assess photoreceptor degeneration and functional outcome measures to determine the drug’s effectiveness.

Published by:

Read more about

This post was originally published on this site